Topic: irritable bowel syndrome with constipation (IBS-C)
The Chinese approval in January opened up a large market with an estimated 14 million irritable bowel syndrome with constipation patients to Linzess.
Novartis' Zelnorm was a steady seller before safety flags pushed it off the market. Now—more than a decade later—can its new owners mount a comeback?
Salix Pharmaceuticals President Mark McKenna is leaving Bausch Health for a precision medicine company.
Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?
Allergan and Ironwood debut a new IBS-C awareness campaign that includes a telemedicine link to talk to a doc online.
Bausch Health is working to pay down debt and focusing on "organic growth," but one analyst says the company hasn't changed much from the old Valeant.
Bausch hopes it can turn around Synergy's struggling constipation drug Trulance to complement its own Xifaxan.
With its Trulance launch on the skids, Synergy is running out of cash and needs to win new debt terms to avoid bankruptcy.
In a new TV ad, people sit on a toilet waiting. They soon emerge smiling and give a fist pump of victory to the tagline, “Say Yes to Linzess.”
Synergy has a new indication for GI med Trulance, and to celebrate, it’s bringing its contract sales force on full time.